Spain-based Almirall has named Peter Guenter as its new chief executive officer, it was reported yesterday.
The new chief executive officer is to succeed Eduardo Sanchiz, who leaves to dedicate more time to other interests.
Guenter joins from Sanofi, where he has worked for the past 22 years, most recently as executive vice president diabetes and cardiovascular global business unit. He earlier held various senior positions at Sanofi, including vice president Eastern Europe and Northern Europe, vice president business management and support, general manager, Germany, and senior vice president, Europe.
Sanchiz will hand over the Almirall leadership to Guenter during September.
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment